Overview

Repeat-Dose Study of Bavituximab in Patients With Chronic Hepatitis C

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety and tolerability of bavituximab when administered via an arm vein as multiple infusions and to examine how bavituximab behaves in the body and how it effects the amount of hepatitis C virus and immune modulators in individuals with chronic infection.
Phase:
Phase 1
Details
Lead Sponsor:
Peregrine Pharmaceuticals
Treatments:
Antibodies, Monoclonal
Bavituximab